Celyad Oncology SA
CYAD
Company Profile
Business description
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates majority of its revenue from Cardiology segment.
Contact
Rue Edouard Belin 2
Axis Business Park
Brabant Wallon
Mont-Saint-Guibert1435
BELT: +32 10394100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
39
Stocks News & Analysis
stocks
What we think of the 3 big winners of the ASX 100
Exploring the ASX companies who dominated the market this year
stocks
Chart of the week: Where do our analysts see value?
This week's chart of the week looks at the under and overvalued sectors in the Australian market.
stocks
Attractive ASX opportunity with high yield
This REIT is undervalued after selloff despite interest-rate and vacancy headwinds.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,550.30 | 36.60 | -0.43% |
| CAC 40 | 7,409.57 | 11.37 | -0.15% |
| DAX 40 | 20,405.92 | 20.35 | -0.10% |
| Dow JONES (US) | 43,828.06 | 86.06 | -0.20% |
| FTSE 100 | 8,300.33 | 11.43 | -0.14% |
| HKSE | 19,971.24 | 425.81 | -2.09% |
| NASDAQ | 19,926.72 | 23.88 | 0.12% |
| Nikkei 225 | 39,470.44 | 378.70 | -0.95% |
| NZX 50 Index | 12,754.26 | 61.54 | 0.48% |
| S&P 500 | 6,051.09 | 0.16 | -0.00% |
| S&P/ASX 200 | 8,296.00 | 34.30 | -0.41% |
| SSE Composite Index | 3,391.88 | 69.62 | -2.01% |